ArticleMicrobial cell factories2013
Evaluation of three industrial Escherichia coli strains in fed-batch cultivations during high-level SOD protein production.
Article in Microbial cell factories, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Refolding, Crystallization, and Crystal Structure Analysis of a Scavenger Receptor Cysteine-Rich Domain of Human Salivary Agglutinin Expressed in Escherichia coli.The protein journal · 2024Article
- Chimeric Protein Switch Biosensors.Advances in biochemical engineering/biotechnology · 2024Review
- An elevated OmpA expression during the production of a recombinant protein in Escherichia coli.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2023Article
- Recombinant Peptide Production SoftensInternational journal of molecular sciences · 2023Article
- Strain specific properties of Escherichia coli can prevent non-canonical amino acid misincorporation caused by scale-related process heterogeneities.Microbial cell factories · 2022Article
- Fusion Tag Design Influences Soluble Recombinant Protein Production inInternational journal of molecular sciences · 2022Article
- Strategies for Enzymatic Inactivation of the Veterinary Antibiotic Florfenicol.Antibiotics (Basel, Switzerland) · 2022Article
- inPOSE: A Flexible Toolbox for Chromosomal Cloning and Amplification of Bacterial Transgenes.Microorganisms · 2022Article
- Article
- Production of Soluble and Functional Anti-TNF-α Fab' Fragment in Cytoplasm of E. coli: Investigating the Effect of Process Conditions on Cellular Biomass and Protein Yield Using Response Surface Methodology.The protein journal · 2021Article
- Designing next generation recombinant protein expression platforms by modulating the cellular stress response in Escherichia coli.Microbial cell factories · 2020Article
- Production of Circularly Permuted Caspase-2 for Affinity Fusion-Tag Removal: Cloning, Expression inBiomolecules · 2020Article
- High-level soluble expression of human Cu,Zn superoxide dismutase with high activity in Escherichia coli.World journal of microbiology & biotechnology · 2020Article
- Development and characterization of Escherichia coli triple reporter strains for investigation of population heterogeneity in bioprocesses.Microbial cell factories · 2020Article
- Design of Experiments As a Tool for Optimization in Recombinant Protein Biotechnology: From Constructs to Crystals.Molecular biotechnology · 2019Review
- Computational Modelling of Metabolic Burden and Substrate Toxicity inMicroorganisms · 2019Article
- Switched reaction specificity in polyesterases towards amide bond hydrolysis by enzyme engineering.RSC advances · 2019Article
- Boosting Recombinant Inclusion Body Production-From Classical Fed-Batch Approach to Continuous Cultivation.Frontiers in bioengineering and biotechnology · 2019Article
- Reteplase: Structure, Function, and Production.Advanced biomedical research · 2019Review
- Dual pathway for metabolic engineering of Escherichia coli to produce the highly valuable hydroxytyrosol.PloS one · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn the biopharmaceutical industry, Escherichia coli (E. coli) strains are among the most frequently used bacterial hosts for producing recombinant proteins because they allow a simple process set-up and they are Food and Drug Administration (FDA)-approved for human applications. Widespread use of E. coli in biotechnology has led to the development of many different strains, and selecting an ideal host to produce a specific protein of interest is an important step in developing a production process. E. coli B and K-12 strains are frequently employed in large-scale production processes, and therefore are of particular interest. We previously evaluated the individual cultivation characteristics of E. coli BL21 and the K-12 hosts RV308 and HMS174. To our knowledge, there has not yet been a detailed comparison of the individual performances of these production strains in terms of recombinant protein production and system stability. The present study directly compared the T7-based expression hosts E. coli BL21(DE3), RV308(DE3), and HMS174(DE3), focusing on evaluating the specific attributes of these strains in relation to high-level protein production of the model protein recombinant human superoxide dismutase (SOD). The experimental setup was an exponential carbon-limited fed-batch cultivation with minimal media and single-pulse induction.
resultsThe host strain BL21(DE3) produced the highest amounts of specific protein, followed by HMS174(DE3) and RV308(DE3). The expression system HMS174(DE3) exhibited system stability by retaining the expression vector over the entire process time; however, it entirely stopped growing shortly after induction. In contrast, BL21(DE3) and RV308(DE3) encountered plasmid loss but maintained growth. RV308(DE3) exhibited the lowest ppGpp concentration, which is correlated with the metabolic stress level and lowest degradation of soluble protein fraction compared to both other strains.
conclusionsOverall, this study provides novel data regarding the individual strain properties and production capabilities, which will enable targeted strain selection for producing a specific protein of interest. This information can be used to accelerate future process design and implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.